TOXICOLOGY ENDPOINT SELECTION DOCUMENT

Chemical Name: Methidathion

PC Code: 100301

Structure:

![Chemical Structure](image)

Methidathion

The Health Effects Division Toxicology Endpoint Selection Committee considered the available toxicology data for Methidathion at a meeting held on June 4, 1996. Based upon a review of the toxicology database for the chemical listed above, toxicology endpoints and dose levels of concern have been identified for use in risk assessments corresponding to the categories below. A brief capsule of the study is presented for use in preparation of risk assessments.

Where no appropriate data have been identified or a risk assessment is not warranted, this is noted. Data required to describe the uncertainties in the risk assessment due to the toxicology database are presented. These include but are not limited to extrapolation from different time frames or conversions due to route differences. If route to route extrapolation is necessary, the data to perform this extrapolation are provided.

TOXICOLOGIST: MELBA S. MORROW (NAME) Date: _____

SECTION HEAD: JOYCELYN E. STEWART (NAME) Date: _____

196
DERMAL ABSORPTION DATA
No studies were available to assess the dermal absorption of methidathion. A 100% dermal absorption was assumed based on the results of a 21 day dermal toxicity study in rabbits in which systemic toxicity was reported at 1 mg/kg/day which represented the lowest dose tested. Systemic toxicity included mortality and clinical signs consistent with cholinesterase inhibition.

MRID: 40079806

% absorbed: assume 100 %

*******************************************************************************

ACUTE DIETARY ENDPOINT (ONE DAY)

Study Selected - Guideline No.: 82-7

MRID No.: 43582501

Summary: When methidathion was administered for 90 days in the diet to male and female Sprague Dawley rats at dose levels of 0, 3, 10, 30 or 100 ppm (equal to 0.2, 0.6, 1.9 or 6.3 mg/kg for males and 0.2, 0.7, 2.0 or 7.2 mg/kg for females), the compound was associated with effects on the FOB in females, only at levels which exceeded the LOEL for systemic toxicity. The NOEL was 3 ppm (0.2 mg/kg) and the LOEL was 10 ppm (0.6 mg/kg) based on statistically and biologically significant decreases in red blood cell, serum and central nervous system cholinesterase activity.

Endpoint and dose for use in risk assessment:
NOEL = 0.2 mg/kg/day based on decreases in serum (24%) and brain (26% decrease in cerebral cortex) cholinesterase activity at a two week measurement.

Comments about study and/or endpoint:
This NOEL and endpoint is supported by the NOEL of < 1.0 mg/kg observed in an acute neurotoxicity study in rats in which a 41% decrease in brain (cerebral cortex) cholinesterase activity was seen at 1.0 mg/kg/day after two weeks and cholinergic signs were seen at 4 mg/kg/day. The doses tested in the acute study were 0, 1, 4, 8 or 16 mg/kg.

This risk assessment is required.

*******************************************************************************

SHORT TERM-, INTERMEDIATE-, AND LONG-TERM OCCUPATIONAL OR RESIDENTIAL EXPOSURE
Study Selected - Guideline No.: 82-7

MRID No.: 43582501

**Summary:** When methidathion was administered for 90 days in the diet to male and female Sprague Dawley rats at dose levels of 0, 3, 10, 30 or 100 ppm (equal to 0.2, 0.6, 1.9 or 6.3 mg/kg for males and 0.2, 0.7, 2.0 or 7.2 mg/kg for females), the compound was associated with effects on the FOB in females, only at levels which exceeded the LOEL for systemic toxicity. The NOEL was 3 ppm (0.2 mg/kg) and the LOEL was 10 ppm (0.6 mg/kg) based on statistically and biologically significant decreases in red blood cell, serum and central nervous system cholinesterase activity.

**Endpoint and dose for use in risk assessment:**
NOEL = 0.2 mg/kg/day based on decreases in serum and regional brain cholinesterase activity at a two week measurement.

**Comments about study and/or endpoint:**
This NOEL and endpoint is supported by the NOEL for cholinesterase inhibition of 1.0 mg/kg observed in a 21 day dermal study. In this study, males exhibited decreases in plasma, red cell and brain cholinesterase activity and females exhibited decreases in red cell and brain cholinesterase activity at the LOEL of 10.0 mg/kg/day. Although the study was classified as supplementary due to a lack of a systemic NOEL, it can be upgraded based on criteria developed during the rejection rate analysis which stated that the lack of a NOEL and the use of an occlusive bandage would not be sufficient reasons to reject a dermal toxicity study.

This risk assessment is required.

**INTERMEDIATE**

**Summary:** See Acute dietary

**Endpoint and dose for use in risk assessment:**
NOEL = 0.2 mg/kg/day based on decreases in cholinesterase activity at a two week measurement.

**Comments about study and/or endpoint:**
This NOEL and endpoint is supported by the cholinesterase NOEL of 1.0 mg/kg observed in a 21 day dermal study. In this study, males exhibited decreases in plasma, red cell and brain cholinesterase activity and females exhibited decreases in red cell and brain cholinesterase activity at the LOEL of 10.0 mg/kg/day. Although the study was classified as supplementary due to a lack of a systemic NOEL, it can be upgraded based on criteria developed during the rejection rate analysis.

This risk assessment is required.

**CHRONIC**

**Summary:** In a one year chronic dog study, methidathion was administered at oral doses of 0, 0.5, 2.0, 4.0, 40.0 or 140 ppm/day. This is equivalent to a mg/kg/day dose of 0, 0.02, 0.07, 0.15, 1.33 or 4.51 for males and 0, 0.02, 0.07, 0.15, 1.39 or 4.9 for females. The NOEL in this study was 4 ppm (0.15) mg/kg/day for both sexes based on
elevation of hepatic enzymes, gross hepatic lesions and microscopic presence of bile plugs, distended bile canaliculi and chronic hepatitis, all occurring at 40 ppm (1.33 mg/kg). At the LOEL of 40 ppm, erythrocyte cholinesterase activity was significantly decreased.

Dose and Endpoint: NOEL = 0.15 mg/kg/day based on liver pathology as discussed in the above summary and on erythrocyte cholinesterase depression.

Comments about dose/study: This study was used to establish the RfD.

This risk assessment is required.

INHALATION EXPOSURE (ANY TIME PERIOD):
A waiver was granted for an acute inhalation study with the technical product. A 50% formulation product (Supracide 50S) was placed in Toxicity category I with an LC50 of 0.0106 mg/L in males and 0.00111 mg/L in females. Toxic signs and necropsy revealed a strong irritation potential in the respiratory, circulatory, excretory, nervous and gastrointestinal systems.

For the risk assessment, the inhalation and dermal components should be added together in the calculation of the mixer, loader, applicator estimates of exposure. The percent absorption for inhalation should be 100% (default value).
**ACUTE TOXICITY ENDPOINTS:**

**Acute Toxicity of Methidathion**

<table>
<thead>
<tr>
<th>Guideline No.</th>
<th>Study Type</th>
<th>MRID #(S)</th>
<th>Results</th>
<th>Toxicity Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>81-1</td>
<td>Acute Oral</td>
<td>00139328</td>
<td>(LD_{50} &gt; 46.1) mg/kg</td>
<td>II</td>
</tr>
<tr>
<td>81-2</td>
<td>Acute Dermal</td>
<td>00139326</td>
<td>(LD_{50} &gt; 1663) mg/kg</td>
<td>II</td>
</tr>
<tr>
<td>81-3</td>
<td>Acute Inhalation</td>
<td>waived</td>
<td>waived</td>
<td>waived</td>
</tr>
<tr>
<td>81-4</td>
<td>Primary Eye Irritation</td>
<td>00159199</td>
<td>mild irritant</td>
<td>III</td>
</tr>
<tr>
<td>81-5</td>
<td>Primary Skin Irritation</td>
<td>00159200</td>
<td>Non-irritant</td>
<td>IV</td>
</tr>
<tr>
<td>81-6</td>
<td>Dermal Sensitization</td>
<td>252433</td>
<td>non-sensitizer</td>
<td>N/A</td>
</tr>
<tr>
<td>81-8</td>
<td>Acute Neurotoxicity</td>
<td>43145903, 43590304</td>
<td>NOEL &lt; 1mg/kg</td>
<td>neurotoxicant</td>
</tr>
</tbody>
</table>